January 10, 2022
Life Sciences
  • Pfizer Inc. will pay up to $1.35 billion to partner with gene-editing specialist Beam Therapeutics Inc. The four-year deal will allow Pfizer to develop three drugs for rare genetic diseases of the liver, muscle, and central nervous system using base editing, a technique for changing DNA that Beam says is less risky than genome-editing approaches like CRISPR. Beam will get $300 million upfront under the agreement, the companies said. (Press release here; Articles here and here)